Trends in COVID-19-associated mortality in patients with pulmonary hypertension: a COMPERA analysis

Kai-Helge Schmidt, Katrin Milger, Christine Pausch, Doerte Huscher, David Pittrow, Ekkehard Grünig, Gerd Staehler, Henning Gall, Oliver Distler, Dirk Skowasch, Michael Halank, Heinrike Wilkens, Matthias Held, Hans Klose, Marius M Hoeper, Kai-Helge Schmidt, Katrin Milger, Christine Pausch, Doerte Huscher, David Pittrow, Ekkehard Grünig, Gerd Staehler, Henning Gall, Oliver Distler, Dirk Skowasch, Michael Halank, Heinrike Wilkens, Matthias Held, Hans Klose, Marius M Hoeper

Abstract

In patients with pulmonary hypertension, the mortality rate associated with COVID-19 has declined sharply with the emergence of the Omicron variants https://bit.ly/42OMsfj

Conflict of interest statement

Conflict of interest: K-H. Schmidt has received fees for lectures and educational events from Abbott, Janssen and MSD. K. Milger has received fees from Actelion, AstraZeneca, GSK, Janssen, MSD, Novartis and Sanofi-Avensis. C. Pausch has no disclosures. D. Huscher has received travel compensation from Shire. D. Pittrow has received fees for consultations from Actelion, Amgen, Aspen, Bayer, Biogen, Boehringer Ingelheim, Daiichi Sankyo, MSD, Novartis, Sanofi-Genzyme, Takeda, Viatris and Zambon. E. Grünig has received fees for lectures and/or consultations from Actelion, Bayer, Ferrer, GSK, Janssen, MSD and Orpha Care. G. Staehler has received honoraria for lectures and/or consultancy for Actelion, Bayer, GSK, Novartis and Pfizer. H. Gall reports personal fees from Actelion, AstraZeneca, Bayer, BMS, GossamerBio, GSK, Janssen-Cilag, Lilly, MSD, Novartis, OMT, Pfizer and United Therapeutics. O. Distler has/had consultancy relationship and/or has received research funding from 4 D Science, Actelion, Active Biotec, Bayer, Biogen Idec, Boehringer Ingelheim Pharma, BMS, ChemoAb, EpiPharm, Ergonex, espeRare foundation, GSK, Genentech/Roche, Inventiva, Janssen, Lilly, medac, MedImmune, Mitsubishi Tanabe, Pharmacyclics, Pfizer, Sanofi, Serodapharm and Sinoxa in the area of potential treatments of scleroderma and its complications, including PAH; and in addition, has a patent mir-29 for the treatment of systemic sclerosis licensed. D. Skowasch received fees for lectures and/or consulting and/or research support to institution from Actelion, Bayer, GSK, Janssen, MSD and Pfizer. M. Halank has received speaker fees and honoraria for consultations from Acceleron, Actelion, AstraZeneca, BerlinChemie, GSK, Janssen and MSD. H. Wilkens received fees for lectures and/or consultations from Actelion, Bayer, Biotest, Boehringer, GSK, Janssen, MSD, Pfizer and Roche. M. Held has received speaker fees and honoraria for consultations from Actelion, Bayer, Boehringer Ingelheim Pharma, GlaxoSmithKline, Janssen, MSD, Novartis, Pfizer, Nycomed, Roche and Servier. H. Klose has received speaker fees and honoraria for consultations from Actelion, Bayer, GSK, Janssen, MSD, Novartis, Pfizer and United Therapeutics. M.M. Hoeper has received fees for lectures and/or consultations from Acceleron, Actelion, AOP Health, Bayer, Ferrer, GSK, Janssen, MSD and Pfizer.

References

    1. Belge C, Quarck R, Godinas L, et al. . COVID-19 in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a reference centre survey. ERJ Open Res 2020; 6: 00520-2020. doi:10.1183/23120541.00520-2020
    1. Sulica R, Cefali F, Motschwiller C, et al. . COVID-19 in pulmonary artery hypertension (PAH) patients: observations from a large PAH center in New York City. Diagnostics (Basel) 2021; 11: 128. doi:10.3390/diagnostics11010128
    1. Mamzer A, Waligora M, Kopec G, et al. . Impact of the COVID-19 pandemic on pulmonary hypertension patients: insights from the BNP-PL National database. Int J Environ Res Public Health 2022; 19: 8423. doi:10.3390/ijerph19148423
    1. Farmakis IT, Karyofyllis P, Frantzeskaki F, et al. . Incidence and outcomes of COVID-19 in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: data from the Hellenic pulmOnary hyPertension rEgistry (HOPE). Hellenic J Cardiol 2022; 64: 93–96. doi:10.1016/j.hjc.2021.10.002
    1. Montani D, Certain MC, Weatherald J, et al. . COVID-19 in patients with pulmonary hypertension: a national prospective cohort study. Am J Respir Crit Care Med 2022; 206: 573–583. doi:10.1164/rccm.202112-2761OC
    1. Nyberg T, Ferguson NM, Nash SG, et al. . Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet 2022; 399: 1303–1312. doi:10.1016/S0140-6736(22)00462-7
    1. Humbert M, Kovacs G, Hoeper MM, et al. . 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022; 43: 3618–3731. doi:10.1093/eurheartj/ehac237
    1. Humbert M, Kovacs G, Hoeper MM, et al. . 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2023; 61: 2200879. doi:10.1183/13993003.00879-2022
    1. Abraham S, Nohria A, Neilan TG, et al. . Cardiovascular drug interactions with nirmatrelvir/ritonavir in patients with COVID-19: JACC review topic of the week. J Am Coll Cardiol 2022; 80: 1912–1924. doi:10.1016/j.jacc.2022.08.800

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel